Glenmark Pharmaceuticals’ subsidiary -- Glenmark Therapeutics Inc., USA has launched Olopatadine Hydrochloride Ophthalmic Solution USP, 0.1% (OTC); compare to the active ingredient in Pataday Twice Daily Relief.
According to Nielsen syndicated data for the latest 52 weeks’ period ending July 13, 2024, the Pataday Twice Daily Relief (OTC) market achieved annual sales of approximately $26.4 million.
In July, the company had received final approval by the United States Food & Drug Administration (U.S. FDA) for Topiramate Capsules USP, 15 mg and 25 mg.
Glenmark Pharmaceuticals is a global research-led pharmaceutical company with presence across Generics, Specialty and OTC business with operations in over 50 countries.
